866-997-4948(US-Canada Toll Free)

2017-2022 Global and Japan Antitumor Drugs of Antimetabolite Class Market Analysis Report

Published By :

Jp Research

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 111 Pages

The global Antitumor Drugs of Antimetabolite Class market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Antitumor Drugs of Antimetabolite Class market's development status and future trend in the global and Japan. It splits Antitumor Drugs of Antimetabolite Class market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
AYUMI Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co.,Ltd
Mitsubishi Tanabe Pharma Corporation
Nichi-iko Pharmaceutical Co.,Ltd
Novartis Pharma K.K.
Pfizer Pharmaceuticals Inc.
POLA PHARMA INC.
Sawai Pharmaceutical Co.,Ltd.
TOWA PHARMACEUTICAL CO., LTD.
TAIHO Pharmaceutical Co.,LTD.
Elmed Eisai Co., Ltd.
NIPRO CORPORATION
NIPPON KAYAKU
Meiji Seika Pharma Co., Ltd.
OKAYAMA TAIHO Pharmaceutical Co., Ltd.

Geographically, this report splits the Global market into the following regions:
Asia Pacific
Japan
Tokyo
Yokohama
Osaka
Nagoya
Others
China
Korea
India
Others
Europe
France
Germany
United Kingdom
Italy
Russia
Others
North America
United States
Canada
Latin America
Brazil
Mexico
Others
Southeast Asia
Singapore
Malaysia
Vietnam
Myanmar
Thailand
Indonesia
Philippines
Others
Middle East & Africa
Saudi Arabia
Iran
UAE
Turkey
Israel
Egypt
South Africa
Others

On the basis of product, the Antitumor Drugs of Antimetabolite Class market is primarily split into
Antitumor Drugs of Antimetabolite Class Market, by Antimetabolite Class
Gemcitabine
Doxifluridine
Methotrexate
Cytarabine
Fludarabine
Vinorelbine
Temozolomide
Clofarabine
Arranon
Ciclosporin
Tegafur
Aminopterin

Key Applications
Oncology Department
Department of Chemotherapy
Pharmacology


Table of Contents

2017-2022 Global and Japan Antitumor Drugs of Antimetabolite Class Market Analysis Report
1 Antitumor Drugs of Antimetabolite Class Overview
1.1 Product Overview and Scope of Antitumor Drugs of Antimetabolite Class
1.2 Global and Japan Antitumor Drugs of Antimetabolite Class Market by Applications/End Users
1.2.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
1.2.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Applications (2012-2017)
1.2.1.2 Japan Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Applications (2012-2017)
1.2.1.3 Market Drivers and Opportunities
1.2.2 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
1.2.3 Global Antitumor Drugs of Antimetabolite Class Sales by Application (2012-2017)
1.2.3.1 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Applications (2012-2017)
1.2.3.2 Global Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Applications (2012-2017)
1.2.3.3 Market Drivers and Opportunities
1.2.4 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
1.2.5 Oncology Department
1.2.6 Department of Chemotherapy
1.2.7 Pharmacology
1.3 Global and Japan Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
1.3.1 Japan Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
1.3.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) (2012-2017)
1.3.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)
1.3.2 Global Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
1.3.2.1 Global Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) (2012-2017)
1.3.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)
1.4 Global and Japan Classification of Antitumor Drugs of Antimetabolite Class by Antimetabolite Class
1.4.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Antimetabolite Class (2012-2017)
1.4.2 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Antimetabolite Class (2012-2017)
1.4.3 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Antimetabolite Class (2012-2017)
1.4.4 Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Antimetabolite Class (2012-2017)
1.4.5 Japan Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)
1.4.6 Global Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)
1.4.7 Japan Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Antimetabolite Class (2012-2017)
1.4.8 Global Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Antimetabolite Class (2012-2017)
1.4.9 Gemcitabine
1.4.10 Doxifluridine
1.4.11 Methotrexate
1.4.12 Cytarabine
1.4.13 Fludarabine
Vinorelbine
Temozolomide
Clofarabine
Arranon
Ciclosporin
Tegafur
Aminopterin

2 Global and Japan Antitumor Drugs of Antimetabolite Class Market Competition by Players/Manufacturers
2.1 Japan Antitumor Drugs of Antimetabolite Class Market Competition by Players/Manufacturers
2.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales and Market Share of Key Players/Manufacturers (2012-2017)
2.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue and Share by Players/Manufacturers (2012-2017)
2.1.3 Japan Antitumor Drugs of Antimetabolite Class Average Price () by Players/Manufacturers (2012-2017)
2.1.4 Japan Antitumor Drugs of Antimetabolite Class Market Competitive Situation and Trends
2.1.4.1 Japan Antitumor Drugs of Antimetabolite Class Market Concentration Rate
2.1.4.2 Japan Antitumor Drugs of Antimetabolite Class Market Share of Top 3 and Top 5 Players/Manufacturers
2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
2.1.5 Japan Players/Manufacturers Antitumor Drugs of Antimetabolite Class Manufacturing Base Distribution, Sales Area, Product Types
2.2 Global Antitumor Drugs of Antimetabolite Class Market Competition by Players/Manufacturers
2.2.1 Global Antitumor Drugs of Antimetabolite Class Sales and Market Share of Key Players/Manufacturers (2012-2017)
2.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue and Share by Players/Manufacturers (2012-2017)
2.2.3 Global Antitumor Drugs of Antimetabolite Class Average Price () by Players/Manufacturers (2012-2017)
2.2.4 Global Antitumor Drugs of Antimetabolite Class Market Competitive Situation and Trends
2.2.4.1 Global Antitumor Drugs of Antimetabolite Class Market Concentration Rate
2.2.4.2 Global Antitumor Drugs of Antimetabolite Class Market Share of Top 3 and Top 5 Players/Manufacturers
2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
2.2.5 Global Players/Manufacturers Antitumor Drugs of Antimetabolite Class Manufacturing Base Distribution, Sales Area, Product Types

3 Global and Japan Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.1 Asia Pacific Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.1.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.1.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.1.1.3 Japan Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.1.2 China Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.1.2.1 China Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.1.2.2 China Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.1.2.3 China Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.1.3 Korea Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.1.3.1 Korea Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.1.3.2 Korea Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.1.3.3 Korea Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.1.4 India Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.1.4.1 India Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.1.4.2 India Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.1.4.3 India Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.1.5 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.1.5.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.1.5.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.1.5.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2 Europe Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.2.1 France Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.1.1 France Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.1.2 France Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.1.3 France Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2.2 Germany Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.2.1 Germany Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.2.2 Germany Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.2.3 Germany Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2.3 United Kingdom Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.3.1 United Kingdom Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.3.2 United Kingdom Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.3.3 United Kingdom Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2.4 Italy Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.4.1 Italy Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.4.2 Italy Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.4.3 Italy Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2.5 Russia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.5.1 Russia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.5.2 Russia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.5.3 Russia Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.2.6 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.2.6.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.2.6.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.2.6.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.3 North America Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.3.1 United States Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.3.1.1 United States Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.3.1.2 United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.3.1.3 United States Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.3.2 Canada Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.3.2.1 Canada Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.3.2.2 Canada Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.3.2.3 Canada Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.4 Latin America Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.4.1 Brazil Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.4.1.1 Brazil Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.4.1.2 Brazil Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.4.1.3 Brazil Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.4.2 Mexico Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.4.2.1 Mexico Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.4.2.2 Mexico Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.4.2.3 Mexico Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.4.3 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.4.3.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.4.3.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.4.3.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5 Southeast Asia Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.5.1 Singapore Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.1.1 Singapore Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.1.2 Singapore Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.1.3 Singapore Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.2 Malaysia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.2.1 Malaysia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.2.2 Malaysia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.2.3 Malaysia Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.3 Vietnam Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.3.1 Vietnam Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.3.2 Vietnam Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.3.3 Vietnam Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.4 Myanmar Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.4.1 Myanmar Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.4.2 Myanmar Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.4.3 Myanmar Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.5 Thailand Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.5.1 Thailand Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.5.2 Thailand Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.5.3 Thailand Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.6 Indonesia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.6.1 Indonesia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.6.2 Indonesia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.6.3 Indonesia Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.7 Philippines Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.7.1 Philippines Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.7.2 Philippines Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.7.3 Philippines Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.5.8 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.5.8.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.5.8.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.5.8.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6 Middle East & Africa Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)
3.6.1 Saudi Arabia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.1.1 Saudi Arabia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.1.2 Saudi Arabia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.1.3 Saudi Arabia Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.2 Iran Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.2.1 Iran Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.2.2 Iran Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.2.3 Iran Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.3 UAE Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.3.1 UAE Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.3.2 UAE Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.3.3 UAE Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.4 Turkey Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.4.1 Turkey Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.4.2 Turkey Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.4.3 Turkey Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.5 Israel Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.5.1 Israel Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.5.2 Israel Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.5.3 Israel Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.6 Egypt Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.6.1 Egypt Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.6.2 Egypt Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.6.3 Egypt Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.7 South Africa Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.7.1 South Africa Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.7.2 South Africa Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.7.3 South Africa Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)
3.6.8 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
3.6.8.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
3.6.8.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
3.6.8.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

4 Global and Japan Antitumor Drugs of Antimetabolite Class Players/Manufacturers Profiles and Sales Data
4.1 AYUMI Pharmaceutical Co., Ltd.
4.1.1 Company Basic Information, Manufacturing Base and Competitors
4.1.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.1.2.1 Product A
4.1.2.2 Product B
4.1.3 AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.1.4 Main Business/Business Overview
4.2 Chugai Pharmaceutical Co., Ltd.
4.2.1 Company Basic Information, Manufacturing Base and Competitors
4.2.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.2.2.1 Product A
4.2.2.2 Product B
4.2.3 Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.2.4 Main Business/Business Overview
4.3 Kyowa Hakko Kirin Co.,Ltd
4.3.1 Company Basic Information, Manufacturing Base and Competitors
4.3.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.3.2.1 Product A
4.3.2.2 Product B
4.3.3 Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.3.4 Main Business/Business Overview
4.4 Mitsubishi Tanabe Pharma Corporation
4.4.1 Company Basic Information, Manufacturing Base and Competitors
4.4.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.4.2.1 Product A
4.4.2.2 Product B
4.4.3 Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.4.4 Main Business/Business Overview
4.5 Nichi-iko Pharmaceutical Co.,Ltd
4.5.1 Company Basic Information, Manufacturing Base and Competitors
4.5.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.5.2.1 Product A
4.5.2.2 Product B
4.5.3 Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.5.4 Main Business/Business Overview
4.6 Novartis Pharma K.K.
4.6.1 Company Basic Information, Manufacturing Base and Competitors
4.6.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.6.2.1 Product A
4.6.2.2 Product B
4.6.3 Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.6.4 Main Business/Business Overview
4.7 Pfizer Pharmaceuticals Inc.
4.7.1 Company Basic Information, Manufacturing Base and Competitors
4.7.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.7.2.1 Product A
4.7.2.2 Product B
4.7.3 Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.7.4 Main Business/Business Overview
4.8 POLA PHARMA INC.
4.8.1 Company Basic Information, Manufacturing Base and Competitors
4.8.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.8.2.1 Product A
4.8.2.2 Product B
4.8.3 POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.8.4 Main Business/Business Overview
4.9 Sawai Pharmaceutical Co.,Ltd.
4.9.1 Company Basic Information, Manufacturing Base and Competitors
4.9.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.9.2.1 Product A
4.9.2.2 Product B
4.9.3 Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.9.4 Main Business/Business Overview
4.10 TOWA PHARMACEUTICAL CO., LTD.
4.10.1 Company Basic Information, Manufacturing Base and Competitors
4.10.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
4.10.2.1 Product A
4.10.2.2 Product B
4.10.3 TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
4.10.4 Main Business/Business Overview
4.11 TAIHO Pharmaceutical Co.,LTD.
4.12 Elmed Eisai Co., Ltd.
4.13 NIPRO CORPORATION
4.14 NIPPON KAYAKU
4.15 Meiji Seika Pharma Co., Ltd.
4.16 OKAYAMA TAIHO Pharmaceutical Co., Ltd.

5 Antitumor Drugs of Antimetabolite Class Manufacturing Cost Analysis
5.1 Antitumor Drugs of Antimetabolite Class Key Raw Materials Analysis
5.1.1 Key Raw Materials
5.1.2 Price Trend of Key Raw Materials
5.1.3 Key Suppliers of Raw Materials
5.1.4 Market Concentration Rate of Raw Materials
5.2 Proportion of Manufacturing Cost Structure
5.2.1 Raw Materials
5.2.2 Labor Cost
5.2.3 Manufacturing Expenses
5.3 Manufacturing Process Analysis of Antitumor Drugs of Antimetabolite Class

6 Industrial Chain, Sourcing Strategy and Downstream Buyers
6.1 Antitumor Drugs of Antimetabolite Class Industrial Chain Analysis
6.2 Upstream Raw Materials Sourcing
6.3 Raw Materials Sources of Antitumor Drugs of Antimetabolite Class Major Players/Manufacturers in 2016
6.4 Downstream Buyers

7 Marketing Strategy Analysis, Distributors/Traders
7.1 Marketing Channel
7.1.1 Direct Marketing
7.1.2 Indirect Marketing
7.1.3 Marketing Channel Development Trend
7.2 Market Positioning
7.2.1 Pricing Strategy
7.2.2 Brand Strategy
7.2.3 Target Client
7.3 Distributors/Traders List

8 Market Effect Factors Analysis
8.1 Technology Progress/Risk
8.1.1 Substitutes Threat
8.1.2 Technology Progress in Related Industry
8.2 Consumer Needs/Customer Preference Change
8.3 Economic/Political Environmental Change

9 Global and Japan Antitumor Drugs of Antimetabolite Class Market Size (Sales and Revenue) Forecast (2017-2022)
9.1 Global and Japan Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)
9.2 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)
9.2.1 by Antimetabolite Class
9.2.2 by
9.3 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
9.4 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

10 Research Findings and Conclusion

11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 Market Size Estimation
11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Disclaimer
11.4 Author List


List of Table

List of Tables and Figures

Figure Product Picture of Antitumor Drugs of Antimetabolite Class
Table Japan Antitumor Drugs of Antimetabolite Class Sales (Million Units) Comparison by Applications (2012-2017)
Figure Japan Sales Market Share (%) of Antitumor Drugs of Antimetabolite Class by Applications in 2016
Table Global Antitumor Drugs of Antimetabolite Class Sales (Million Units) Comparison by Applications (2012-2017)
Figure Global Sales Market Share (%) of Antitumor Drugs of Antimetabolite Class by Applications in 2016
Figure Oncology Department Examples
Table Key Downstream Customer in Oncology Department
Figure Department of Chemotherapy Examples
Table Key Downstream Customer in Department of Chemotherapy
Figure Pharmacology Examples
Table Key Downstream Customer in Pharmacology
Figure Gemcitabine Product Picture
Figure Doxifluridine Product Picture
Figure Methotrexate Product Picture
Figure Cytarabine Product Picture
Figure Fludarabine Product Picture
Figure Product Picture
Figure Product Picture
Table AYUMI Pharmaceutical Co., Ltd. Basic Information List
Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Chugai Pharmaceutical Co., Ltd. Basic Information List
Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Kyowa Hakko Kirin Co.,Ltd Basic Information List
Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Mitsubishi Tanabe Pharma Corporation Basic Information List
Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Nichi-iko Pharmaceutical Co.,Ltd Basic Information List
Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Novartis Pharma K.K. Basic Information List
Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Pfizer Pharmaceuticals Inc. Basic Information List
Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table POLA PHARMA INC. Basic Information List
Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table Sawai Pharmaceutical Co.,Ltd. Basic Information List
Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table TOWA PHARMACEUTICAL CO., LTD. Basic Information List
Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)
Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)
Figure TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)
Table TAIHO Pharmaceutical Co.,LTD. Basic Information List
Table Elmed Eisai Co., Ltd. Basic Information List
Table NIPRO CORPORATION Basic Information List
Table NIPPON KAYAKU Basic Information List
Table Meiji Seika Pharma Co., Ltd. Basic Information List
Table OKAYAMA TAIHO Pharmaceutical Co., Ltd. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Antitumor Drugs of Antimetabolite Class
Figure Manufacturing Process Analysis of Antitumor Drugs of Antimetabolite Class
Figure Antitumor Drugs of Antimetabolite Class Industrial Chain Analysis
Table Raw Materials Sources of Antitumor Drugs of Antimetabolite Class Major Players/Manufacturers in 2016
Table Major Buyers of Antitumor Drugs of Antimetabolite Class
Table Distributors/Traders List
Figure Japan Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)
Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Type in 2017
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Type in 2017
Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2017
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2017
Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
Table Japan Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *